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ABSTRACT 
 
A minority of meningiomas are difficult to treat with surgery or radiotherapy, and 
chemotherapeutic alternatives are limited. This study aims to better understand pathways that 
are active in meningiomas, in order to direct future treatment strategies. We investigated the 
expression and activation of multiple growth factor receptors, their ligands and downstream 
signalling pathways in 30 meningiomas using immunohistochemistry. Expression was 
correlated with chromosome 22q loss. Membrane expression of VEGFR and PDGFR was 
seen in 83% of tumours, Axl in 70%, EGFR in 50% and IGFR in 47%. Expression was similar 
in low and high grade tumours, but membrane EGFR expression was not seen in tumours 
showing chromosome 22q loss (p<0.05). Expression of ligands IGF, NRG, VEGF, Gas 6, and 
signalling proteins, Mek, Erk, Jnk and Akt, and pS6RP, was widespread. Western blot 
confirmed widespread Axl expression and supported selective expression of EGFR in NF2-
intact meningiomas. The majority of meningiomas express and show activation of multiple 
growth factor receptors and their signalling pathways, irrespective of tumour grade. In addition 
to previously reported receptors, Axl offers a new therapeutic target. The findings also suggest 
that anti-EGFR based therapies may be less effective in meningiomas with 22q loss.   
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INTRODUCTION 
Meningiomas represent the most common primary intracranial neoplasm accounting for up to 
34% of all tumours 
1
. Although many maybe effectively treated surgically, a significant 
number are either surgically inaccessible or recur, particularly the 20-35% which are either 
histologically atypical or malignant 
2
. In addition, in approximately 10% of cases, 
meningiomas are multiple, particularly in familial tumour syndromes such as 
neurofibromatosis type 2. Treatment of recurrent, multiple and surgically inaccessible tumours 
is difficult as chemotherapeutic regimes are of limited benefit 
3
 and radiotherapy is associated 
with significant morbidity in a proportion of patients, even when given stereotactically 
4
. 
Chromosome 22q losses are a common abnormality occurring in approximately 60% of 
sporadic tumours, most of which have been shown to also have mutations or methylation of the 
remaining neurofibromatosis type 2 (NF2) gene locus, leading to gene inactivation
5, 6
. Much 
work has been done by ourselves and others on the function of the NF2 gene product Merlin, 
and how its loss leads to expression of a number of growth factors and their downstream 
signalling pathways 
7-9
. Although most of this work has been carried out in relation to 
schwannomas, the findings suggest that Merlin-deficient tumours may be susceptible to a 
number of new therapeutic strategies directed at components of these pathways 
10
. Recently a 
number of other genes, including AKT1, SMO, TRAF7, KLF4 and SMARCB1 have been shown 
to be defective in NF2-intact meningiomas 
11, 12
, but it is not clear whether this group of 
meningiomas differ in their pathway activation. The aim of the current study is to broadly 
assess the expression of a number of these growth factors, their receptors including their 
phosphorylation status, and downstream signalling molecules, in meningiomas of all grades 
(see Figure 1). In addition, we have compared a group of meningiomas known to have a high 
rate of NF2 gene inactivation, with meningiomas known to have a low rate 
5, 13-15
, in order to 
assess whether expression of these markers differs significantly between these two groups, and 
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also compared expression with WHO Grade II and III meningiomas and non-neoplastic 
meninges.  
 
MATERIALS AND METHODS 
 
Cases and tissue samples 
Local research ethics approval was obtained for the study. Formalin fixed paraffin embedded 
tissue samples from 30 meningiomas were retrieved from the archives of the Department of 
Cellular & Anatomical Pathology, Derriford Hospital, Plymouth, UK. Cases were identified 
following a SNOMED search of the histology archives. 20 tumours were of WHO Grade I 
histological subtype and were selected to include 10 cases associated with a high rate of NF2 
gene abnormalities (fibroblastic meningiomas, transitional meningiomas and meningiomas in 
patients with neurofibromatosis type 2) and 10 cases with a low rate of NF2 gene mutations 
(secretory meningiomas and meningothelial meningiomas). In addition 10 high grade 
meningiomas (5 atypical 5 anaplastic meningiomas) were included. 10 cortical brain biopsies 
including strips of arachnoid, acted as controls. 
 
Immunohistochemistry 
4m paraffin sections were de-waxed, re-hydrated and incubated with primary antibodies at 
room temperature overnight using the antigen retrieval methods and titres indicated below, as 
previously described 
16, 17
. Antibodies to the following growth factors and receptors were 
examined: phosphorylated platelet-derived growth factor receptor  (pPDGFRβ, Y857, 
Abcam, 1:800, 30 minutes EDTA pH9.0 and Y751, Abcam, 1:1000, 30 minutes EDTA); 
phosphorylated insulin-like growth factor 1 receptor (pIGF1R, Abcam, 1:50, 30 minutes citrate 
pH6.0); insulin-like growth factor 1 (IGF1, Abcam, 1:200, 30 minutes citrate pH6); insulin-like 
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growth factor 2 (IGF2, Abcam, 1:250, 30 minutes citrate pH6); phosphorylated human 
epidermal growth factor receptor 2 (pErbB2, Cell Signalling, 1:50, 10 minutes trypsin); 
neuregulin 1 (NRG, Abcam, 1:70, 30 minutes EDTA pH9.0); phosphorylated human epidermal 
growth factor receptor 1 (pEGFR, Y845, R&D systems, 1:200, 30 minutes EDTA pH9.0); 
phosphorylated vascular endothelial growth factor receptor 1 (VEGFR1p, Abcam, 1:100, 30 
minutes EDTA pH9.0); phosphorylated vascular endothelial growth factor receptor 2 
(VEGFR2p, Abcam, 1:100, 30 minutes EDTA pH9.0). Antibodies to the following protein 
kinases and signalling molecules were used; pMek (Cell Signalling, 1:600, 30 minutes EDTA 
pH9.0); mitogen activated protein kinase (Erk/MAPK, Abcam,1:500, 30 minutes EDTA 
pH9.0); phosphorylated mitogen activated protein kinase (pErk/MAPK, Promega, 1:500, 30 
minutes EDTA pH9.0); pAkt (Santa Cruz, 1:100, 20 minutes DAKO antigen retrieval 
solution); pJnk (Cell Signalling,  1:100, 20 minutes DAKO antigen retrieval solution); Axl 
(R&D systems, 1:75, 30 minutes EDTA pH9.0); pAxl (R&D systems, 1:7500, 10 minutes 
EDTA pH9.0); Mer (Abnova, 1:100,  20 minutes DAKO antigen retrieval solution); growth 
arrest specific 6 (Gas 6, Sigma, 1:500, 30 minutes EDTA pH9.0); phosphorylated S6 ribosomal 
protein (pS6RP, Cell Signalling, 1:1000, 30 minutes EDTA pH9.0). 
 
Avidin-biotin blocking solution was used to block non-specific signal with EDTA 
pretreatment. Sections were incubated with appropriate biotin-labelled secondary antibody and 
with horseradish peroxidase for detection using Vectashield Elite according to the 
manufacturer’s protocol. As a control, sections were incubated with omission of the primary 
antibody. The immunohistochemical results were reviewed by two neuropathologists (DAH 
and AS). With some antibodies there was stronger immunoreactivity at the periphery of tissue 
fragments, which was presumed to be related to better preservation of antigen due to more 
rapid fixation. Semiquantitaive assessment of the proportion of the tumour sample that stained 
positive was undertaken and scored as follows: 0 if  less than 5% of tumour cells showed 
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immunoreactivity; 1 if 5-25% of the tumour was positive; 2 if 26-50% was positive; 3 if 51-
75% was positive and 4 if >75% was positive. Membrane staining was generally very focal 
within the tumour, so this was scored as being either present or absent for each of the 
membrane receptors. 
 
Western blot analysis 
Primary cell cultures, derived from 6 meningiomas, were grown in T25 flasks (Greiner Bio-
One) until confluent, lysed with RIPA buffer and protein concentrations were determined with 
a detergent compatible protein assay (Bio-Rad Laboratories, Hercules, CA). 20ug of each 
sample was separated a pre-cast 4-15% gradient gel (Bio-Rad). Blocking was done in 5% milk, 
2% BSA in 0.1% tween in TBS for 1 hour at RT. Membranes were incubated with anti-NF2 
(Cell Signalling, 1:1000) and either anti-pAXL (1µg/ ml, R and D systems) or anti-pErbB2 
(Cell Signalling,1:50). GAPDH was used as a loading control in all cases (1: 20000, Millipore) 
before incubation with appropriate HRP-conjugated secondary antibodies (Bio-Rad). ECL 
(Amersham Biosciences) was used for detection. Insufficient lysate was obtained from some 
tumours to allow both pAxl and pErbB2 to be assessed. 
 
In situ hybridisation 
Fluorescent in situ hybridisation (FISH) was undertaken using a probe to chromosome arm 22q 
as a marker of chromosome 22 loss (Vysis LSI 22q, BCR, spectrum green probe). FISH was 
carried out largely according to the manufacturer’s instructions. Briefly dewaxed 5m paraffin 
sections were heated in a pressure cooker for 5 minutes in citrate buffer at pH6 and then 
digested in 0.4% pepsin at 37C for 10 minutes. Dehydrated sections were then co-denatured 
with probe at 75C for 10 minutes and hybridised overnight. Unbound probe was washed off 
using the manufacturer’s wash solutions and the sections were mounted with DAPI antifade 
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solution. The sections were viewed with a Leica DMRB fluorescent microscope using an x100 
objective and spectrum green filters. A minimum of 100 tumour cell nuclei were assessed and 
tumours with greater than 50% of cells showing a single signal were regarded as showing 
monosomy. All sections were analysed by a pathologist blind to the original diagnosis and any 
of the other results.  
 
Statistical analysis 
Qualitative variables were binary coded and, along with the quantitative expression scores, 
read into SPSS datasheet for statistical analysis. Pearson Chi-Square was used to test for 
association between each of the meningioma groups and the nominal variables. Fisher’s exact 
test was used when the expected counts were small.  For quantitative variables, possible 
differences in the expression between groups of meningioma were tested using non-parametric 
(Mann-Whitney) test. A 5% level of significance was considered in all tests and p-values were 
reported whenever appropriate. Statistical analysis was carried out using SPSS V21.0. 
 
RESULTS 
Growth factor receptors and ligands 
Expression of IGF1 and 2 was seen in varying intensities in the cytoplasm of all tumours.  
IGF1 and IGF2 gave granular cytoplasmic and nuclear immunoreactivity in tumour cells, 
whereas pIGF1R was predominantly nuclear in many tumour cells, with focal membrane 
staining in some (Figure 2A and B).  Neuregulin gave weak, diffuse or granular cytoplasmic 
immunoreactivity in many tumour cells (Figure 2C), but was also seen in normal meninges. 
pEGFR and pErbB2 immunoreactivity was predominantly cytoplasmic in both tumours and 
control tissue, with focal areas of membrane staining in some of tumour cells (Figure 2D and 
E). Relatively weak cytoplasmic and membrane expression of Gas 6 was seen focally in about 
half of the tumours, and some of the non-neoplastic leptopmeninges. Looking at TAM 
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receptors, Axl and pAxl gave widespread, but generally weak, diffuse cytoplasmic staining, 
and in some tumours variable membrane and nuclear staining. pAxl produced the more intense 
membrane (Figure 2F) and nuclear immunoreactivity. Mer expression was variable within the 
cytoplasm and nuclei of tumour cells, and rarely seen in non-neoplastic leptomeninges, but was 
strong within infiltrating macrophages and mast cells.  
 
pPDGFRβ immunoreactivity was widespread in tumour nuclei and diffusely within the 
cytoplasm, but more localised and often granular in tumour membranes and endothelial cells.  
pPDGFRβ immunoreactivity was more intense with the antibody recognising phosphorylation 
at Y857 than the Y751 (Figure 3A).  Antibodies to pVEGFR1p and pVEGFR2p gave very 
similar results with a mixture of nuclear, cytoplasmic and coarse granular membrane 
immunoreactivity in both tumour cells and vasculature (Figure 3B).  Non-neoplastic 
leptomeninges showed some nuclear and cytoplasmic immunoreactivity with these receptor 
antibodies, but did not show any membrane immunoreactivity, apart from one case showing 
focal pVEGFR2p membrane immunoreactivity. A summary of the proportion of tumours 
showing growth factor receptor membrane immunoreactivity is shown in the table. 
 
Activation of downstream signalling pathways 
Analysing downstream signalling pathways, pMek gave strong nuclear and variable 
cytoplasmic immunoreactivity (Figure 4A). Widespread Erk immunoreactivity, with the non-
phosphorylated form being predominantly cytoplasmic, whereas the phosphorylated form was 
predominantly nuclear in localisation with patchy cytoplasmic and membrane 
immunoreactivity (Figure 4B). In several tumours pErk showed areas of very strong 
immunoreactivity intermingled with areas of tumour which were negative. Control 
leptomeninges showed patchy cytoplasmic and nuclear pErk  immunoreactivity.  pJnk 
immunoreactivity was weak and patchy within the nuclei and cytoplasmic in both the tumours  
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and control leptomeninges. pAkt  immunoreactivity was weak and patchy, but sometimes 
strong within the nuclei in both the tumours (Figure 4C) and control leptomeninges. pS6RP 
expression was cytoplasmic, sometimes perinuclear in distribution (Figure 4D). pS6RP 
immunoreactivity was also seen in endothelial cells, macrophages, and weak staining was seen 
in some of the control leptomeninges. 
 
No significant staining was seen following with omission of the primary antibodies. 
 
In view of the novel finding of pAxl expression in the majority of meningiomas and the 
selective membrane expression of pErbB2 in tumours without 22q loss, these proteins were 
further analysed by Western blot using primary meningioma cell cultures. The findings 
supported the immunohistochemical observations with widespread pAxl expression in NF2-
intact and deficient meningiomas, and limited expression pErbB2 to one NF2-intact 
meningioma (Figure 5A and B). 
 
FISH analysis revealed loss from chromosome arm 22q, in 70% of the group of meningiomas 
expected to have a high rate of NF2 gene inactivation (fibroblastic meningiomas, transitional 
meningiomas and meningiomas in patients with neurofibromatosis type 2), and in 10% group 
of meningiomas expected to have a low rate of NF2 gene inactivation (secretory meningiomas 
and meningothelial meningiomas). 4 out of 10 high grade meningiomas showed 22q loss. 
Polyploidy was noted in several of the tumours. Semi-quantitative scoring of staining intensity 
and distribution was difficult due to variable tissue preservation of antigen, but was scored for 
each of the markers, and in addition for the majority of the growth factor receptors the presence 
or absence of membrane immunoreactivity was also noted (see Appendix for scores).  There 
were significant differences in intensity of expression of many of the markers between tumour 
and non-neoplastic meninges (pS6RP, pAxl, membrane staining of pIGFR and pErbB2 p<0.05; 
10 
 
IGF1, Erk and membrane staining of Axl p<0.005;  pEGFR, Mer, pVEGFR1p, pVEGFR2p 
and membrane staining of pPDGFRβY857, pVEGFR1p, pVEGFR2p and pAxl p<0.001). 
When comparing WHO grade I with WHO grade II/III tumours there were significant 
reductions in the intensity of non-membrane expression of some of the receptors in higher 
grade tumours (pErbB2, Mer p<0.001; pVEGFR2p p<0.005), reduction in membrane 
expression of pVEGFR1p (p<0.05), and increased non-membrane expression of 
pPDGFRβY751 (p<0.005). No other differences were found between tumour grades.  An 
increase pErk and pS6RP immunoreactivity was seen (P<0.05) in tumours with 22q loss. 
Assessment of the clinical relevance of these semiquantitative differences in immunoreactivity 
is unclear due to the variation in antigen preservation within tissue samples. However, a clear 
difference between 22q-intact and deleted cases was that membrane expression of pEGFR and 
pErbB2 was only seen in tumours without 22q loss (p<0.05 and 0.005 respectively, see Table). 
 
DISCUSSION 
Previous studies have looked at the expression of some of these markers in meningiomas, 
however, none has looked at the wide range that we assessed. In addition we have correlated 
expression with presumed NF2 gene status, and where possible, we have used antibodies to the 
activated (phosphorylated) forms of receptors, and also looked at expression of ligands and 
downstream signalling pathways. Our findings indicate that most meningiomas co-express 
multiple growth factors in their phosphorylated form along with the downstream pathways, 
suggesting that expression is functionally significant. Although expression of many of the 
growth factors was similar in tumours with and without 22q loss, there was  
evidence of differential expression epidermal growth factor receptors between these groups.  
 
Previous studies looking at the expression of platelet derived growth factor and it’s receptor in 
meningiomas have demonstrated the widespread expression of these molecules in most 
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meningiomas 
18, 19
, particularly the beta receptor, in meningiomas of all grades 
20
. In addition 
there is in vitro evidence suggesting autocrine activity 
21
 which may be blocked with specific 
inhibitors 
22
. Other studies have also shown a high rate expression of insulin-like growth factor 
and its receptor 
23-25
, and there is in vitro evidence of its functionality in meningioma cell 
cultures 
24
. Rates of expression of epidermal growth factor and its receptor are more variable, 
although most studies have found expression in the majority (45-100%) of cases of all grades 
24-29
.  ErbB2 protein and gene over-expression have been reported in between 2 and 86% of 
meningiomas 
30-32
. Vascular endothelial growth factor and its receptors have also been shown 
to be present in the majority of meningiomas of all grades, with degree of expression 
correlating with peritumoural oedema 
25, 33
. A recent study has suggested that inhibition of 
these pathways may slow tumour cell migration and proliferation 
34
. The findings in our study 
support the findings in previous reports, but in addition indicate that co-expression of multiple 
and, importantly, activated growth factor-receptor pathways, is a common feature of 
meningiomas. Most previous studies have assessed both cytoplasmic and membrane receptor 
immunoreactivity, and although the significance of the nuclear immunoreactivity is unclear, 
this has also been seen in previous studies on meningiomas 
33, 35
, and nuclear localisation has 
also been reported for a growth factor receptors in non-neoplastic tissues 
36, 37
.  
 
Relatively few previous studies have looked at the expression of downstream signalling 
molecules, in particular protein kinases, in meningiomas 
38, 39
, but their findings suggest that 
levels of expression is higher in WHO Grade II and III tumours. Our findings have 
demonstrated the expression of phosphorylated Jnk and Mek, in addition to Erk, pS6RP and 
Akt, in the majority of meningiomas of all grades. The expression of Ras/Raf/Mek/Erk, the 
Pi3K/Akt/mTOR/ pS6RP signalling pathways supports the suggestion that the growth factors 
and their ligands are functional in meningiomas, a conclusion that is further supported by data 
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to suggest that specific inhibition of these signalling pathways may reduce meningioma cell 
proliferation in vitro 
38, 40
.  
 
Chromosome 22q/NF2 gene abnormalities occur in approximately 60% of sporadic 
meningiomas, which has been shown to correlate with reduced expression of merlin  
41-43
, 
however, this varies with tumour subtype, with losses and/or NF2 mutations in 70-80% of 
fibroblastic and transitional meningiomas, around 25% meningothelial meningiomas, but rare 
in secretory meningiomas  
5, 15, 44
. As we used archived samples we selected two groups of 
meningiomas with high and low rates of NF2 gene abnormalities for comparison, of growth 
factor receptor expression. FISH, using a 300kb probe to 22q11.2, showed evidence of loss in 
7/10 of the meningiomas expected to have a high rate of NF2 gene abnormalities and 1/10 
meningiomas expected to have a low rate. In the atypical/malignant subgroup, 4/10 showed 
evidence of 22q loss. An interesting and unexpected finding was that membrane expression of 
epidermal growth factor receptors was only seen in meningiomas without 22q loss. Previous 
studies on meningiomas have not distinguished membrane from cytoplasmic 
immunoreactivity, however, membrane staining appears to be significant as a predictor of 
tumour response to anti-EGFR therapies treatment in breast tumours 
45
.  Although cytoplasmic 
expression of EGFR was seen in 9/11 tumours showing 22q loss, no membrane expression of 
either EGFR or ErbB2 was seen in this group. The reason for this observation and the higher 
levels of pErbB2 in tumours expressing merlin is unclear, and could be related directly to 
merlin or secondary to other genetic changes seen in meningiomas
11, 12
. However, it is known 
that merlin interacts with ErbB2 at the cell membrane
46
 and may mediate cell-cell contact 
mediated inhibition of EGFR signalling by sequestering activated EGFR to the cell 
membrane
47
 and it has been shown that cells with merlin loss also have increased membrane 
expression of ErbB2
48
. This differential expression may indicate a possibility for 
therapeutically relevant stratification as ErbB2 inhibitors are used clinically. A previous study 
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which looked at the expression of the platelet derived growth factor and it’s receptor and 
correlated expression with monosomy of chromosome 22 and, like us, did not find a significant 
relationship 
18
. However, another recent study found that meningiomas with monosomy of 
chromosome 22 had higher levels of PDGFRβ than those without, and meningiomas with 
multiple chromosomal changes had reduced ErbB2 levels 
49
, and although tumours with 22q 
loss had lower median levels of ErbB2 than diploid tumours, this was not statistically 
significant.   Larger studies of well characterised genetic sub-groups of meningiomas will be 
required to confirm, and better understand, this relationship. 
 
Axl expression has been shown to be important in a wide range of other tumours 
50-53
, 
including merlin deficient tumours such as schwannomas and mesotheliomas 
50, 54, 55
, but there 
are no data available for its potential role meningiomas. The frequent expression of Axl found 
in meningiomas in our study, suggests that further study of its potential role in meningioma 
growth is warranted, and if a functional role is confirmed then it offers further therapeutic 
options 
56, 57
.  
 
These findings are strongly suggestive of a largely autocrine mediated activation of multiple 
growth factor receptors and their signalling pathways being significant in the growth of 
meningiomas. Activation of multiple pathways also suggests that combination therapy against 
multiple growth factors/receptors, or their common signalling pathways 
10, 58
 may be the most 
effective approach to treatment, and may explain the disappointing results of single pathway 
inhibitors such as the PDGFR inhibitor, imatinib mesylate  
59
, VEGF inhibitor, bevacizumab 
60
 
and EGFR inhibitors, gefitinib and erolotinib 
61
.  The lack of membrane expression of pEGFR 
and pErB2 in tumours with loss of 22q, suggests that this group of meningiomas may be less 
responsive to EGFR inhibitors. 
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Figure Legends 
 
Fig. 1 
Diagram showing the relationships between the cell-surface receptor tyrosine kinases 
(PDGFRβ, IGF-1R, ErbB2, VEGFR 1/2 and Axl), their ligands (PDGF, IGF-1, IGF–2, EGF, 
NRG, VEGF and Gas 6) and signal-transduction pathways (Mek1/2, Erk1/2, Jnk, 
PI3K/Akt/S6RP) (Black colour indicates proteins which were investigated in this study). 
Fig. 2 
Expression of ligands and receptors in meningiomas: widespread diffuse granular cytoplasmic 
IGF1 immunoreactivity (A) and strong nuclear and focal membrane pIGF1R immunoreactivity 
(B) within the same tumour; weak, diffuse cytoplasmic neuregulin immunoreactivity (C), both 
weak cytoplasmic and strong membrane pErbB2 immunoreactivity (D) and moderate 
cytoplasmic and membrane pEGFR immunoreactivity (E) in chromosome 22q-intact tumours; 
and strong membrane pAxl immunoreactivity (F), which was seen in 22q-intact and deleted 
tumours. Scale bar 50 µm. 
 
Fig. 3 
Co-expression of pPDGFRβ (A) and pVEGFR2p (B) in a meningioma, weak nuclear and 
cytoplasmic tumour immunoreactivity, with patchy stronger coarse granular membrane 
immunoreactivity. Strong endothelial immunoreactivity is also seen. Scale bar 50 µm. 
 
Fig. 4 
Co-expression of multiple downstream transcription factors in a meningioma: Strong nuclear 
and weak cytoplasmic pMek immunoreactivity (A), focal strong nuclear, and weaker more 
diffuse cytoplasmic  pErk immunoreactivity (B), strong nuclear pAkt immunoreactivity, (C) 
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and diffuse granular cytoplasmic S6RP immunoreactivity (D). Scale bar 50 µm A-C and 25 µm 
D. 
 
Fig. 5 
Western blot analysis of primary meningioma cell cultures demonstrating variable intensity, 
but widespread, pAxl expression in all tumour samples (A).  pErbB2 is only detected within 
one of two NF2 expressing tumours (B). GAPDH used as control and NF2 gene product, 
merlin, also demonstrated. 
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